Emerging Technology Reports

The Emerging Technology Report provides regular updates about emerging and potentially disruptive technologies that are likely to have a significant impact in healthcare. This “early warning” report monitors new health technologies from 6 months to 2 years within a regulatory submission and tracks those as they go through clinical trial development and the regulatory approval process.

For each emerging technology, our analysts describe the technology and intended use, its prospects relative to the regulatory process and FDA information, competing technologies, relevant clinical guidelines, high-level look at the evidence such as published abstracts in the medical literature and available meeting abstracts, and available clinical trials.

Enroute Transcarotid Neuroprotection System (NPS)

The Enroute NPS (formerly the MICHI Neuroprotection System) protects the brain from plaque and debris dislodged during carotid artery angioplasty and stenting (CAS) by reversing blood flow and capturing the material in its in-line filter. It is the first and only embolic protection device for CAS designed for neck rather than groin access. The Enroute NPS device was introduced to the U.S. mark…

ReShape Integrated Dual Balloon System

The ReShape Dual Balloon is an endoscopically placed, temporary dual intragastric balloon. It is intended as an adjunct to diet and exercise in the treatment of obesity.

Uptravi (Selexipag)

Selexipag is a first-in-class oral, nonprostanoid selective IP receptor agonist for treatment of pulmonary arterial hypertension.

Evera MRI SureScan ICD System

The Evera MRI SureScan system is an implantable cardioverter-defibrillator system designed to enable implanted patients to undergo full-body magnetic resonance imaging examinations under prescribed conditions. 

Wearable Artificial Kidney

A wearable miniaturized dialysis system proposed for treatment of patients with end-stage renal disease.

Tagrisso (Osimertinib; Formerly AZD9291)

Tagrisso is a third-generation oral tyrosine kinase inhibitor (TKI) for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR TKI therapy.